Journal article
Allogeneic islet cells implant on poly-l-lactide matrix to reduce hyperglycaemia in streptozotocin-induced diabetic rat.
- Hendrawan S Tarumanagara Human Cell Technology Laboratory, Faculty of Medicine, Tarumanagara University, Indonesia; Postgraduate School, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. Electronic address: siufui@gmail.com.
- Yusuf I Department of Physiology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. Electronic address: irawanyusufgenome@gmail.com.
- Hatta M Molecular Biology and Immunology Laboratory, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. Electronic address: hattaram@indosat.net.id.
- Aman M Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. Electronic address: makbul_aman@yahoo.com.
- Patellongi I Department of Physiology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. Electronic address: ilham_pt@yahoo.com.
- Serra AL Epidemiology, Biostatistics, and Prevention Institute, University of Zurich, Switzerland. Electronic address: andreas.serra@uzh.ch.
- Lawrence G Department of Anatomic Pathology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. Electronic address: gatot.law@gmail.com.
- Weber U Baermed, Center of Abdominal Surgery, Hirslanden Clinic Zurich and University of Bern, Switzerland. Electronic address: uweber159@gmail.com.
- Sutedja B Department of Surgery, Gading Pluit Hospital, Jakarta, Indonesia. Electronic address: dr.barlian@pluit-hospital.com.
- Baer HU Baermed, Center of Abdominal Surgery, Hirslanden Clinic Zurich and University of Bern, Switzerland. Electronic address: hans.baer@baermed.ch.
- 2017-03-29
Published in:
- Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]. - 2017
Diabetes
Glycaemic control
Islet matrix implant
Rat
Animals
Blood Glucose
Body Weight
Cell Culture Techniques
Cell Separation
Cell Survival
Diabetes Mellitus, Experimental
Hyperglycemia
Insulin
Islets of Langerhans
Islets of Langerhans Transplantation
Male
Polyesters
Rats
Rats, Sprague-Dawley
English
OBJECTIVE
To demonstrate the effects of allogeneic islet cell matrix implants for glycaemic control in rats with induced diabetes.
METHOD
Sprague-Dawley rats were used as allogeneic donors of islet cells. Cells were seeded on three-dimensional proprietary poly-(l-lactide) matrices. Animals were rendered diabetic and a week later a matrix seeded with islet cells (IMI group) or a control matrix (placebo group) was implanted in the small bowel mesentery. Blood glucose levels were measured weekly for 12 weeks. After sacrifice, implant sections were Gomori stained for beta-cells and immuno-stained for insulin 3, 4, 5, and 6 months post implantation.
RESULTS
82% of seeded islet cells attached to the matrices. In the IMI group blood glucose levels were significantly reduced after implantation compared with before implantation across several time points. In the IMI group beta-cells and insulin-positive cells were identified at the implant site.
CONCLUSION
The islet cell matrix implant reduced the blood glucose levels although complete normo-glycaemia was not established. The islet cell matrix implant may serve as an additional option for islet cell transplantation using 3D scaffold platforms for better survival and function of the islet cells.
To demonstrate the effects of allogeneic islet cell matrix implants for glycaemic control in rats with induced diabetes.
METHOD
Sprague-Dawley rats were used as allogeneic donors of islet cells. Cells were seeded on three-dimensional proprietary poly-(l-lactide) matrices. Animals were rendered diabetic and a week later a matrix seeded with islet cells (IMI group) or a control matrix (placebo group) was implanted in the small bowel mesentery. Blood glucose levels were measured weekly for 12 weeks. After sacrifice, implant sections were Gomori stained for beta-cells and immuno-stained for insulin 3, 4, 5, and 6 months post implantation.
RESULTS
82% of seeded islet cells attached to the matrices. In the IMI group blood glucose levels were significantly reduced after implantation compared with before implantation across several time points. In the IMI group beta-cells and insulin-positive cells were identified at the implant site.
CONCLUSION
The islet cell matrix implant reduced the blood glucose levels although complete normo-glycaemia was not established. The islet cell matrix implant may serve as an additional option for islet cell transplantation using 3D scaffold platforms for better survival and function of the islet cells.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1016/j.pan.2017.02.017
- PMID 28347646
- Persistent URL
- https://sonar.ch/global/documents/185157
Statistics
Document views: 18
File downloads: